Combining Hepatitis B Virus RNA and Hepatitis B Core–Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen–Positive Patients With Chronic Hepatitis B

Abstract Background Safe nucleos(t)ide analogue discontinuation in chronic hepatitis B (CHB) is an unmet need. We aimed to investigate whether combining hepatitis B virus (HBV) RNA and hepatitis B core–related antigen (HBcrAg) could perform satisfactorily in predicting off-treatment outcomes. Method...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2020-07, Vol.222 (4), p.611-618
Main Authors: Fan, Rong, Peng, Jie, Xie, Qing, Tan, Deming, Xu, Min, Niu, Junqi, Wang, Hao, Ren, Hong, Chen, Xinyue, Wang, Maorong, Sheng, Jifang, Tang, Hong, Bai, Xuefan, Wu, Yaobo, Zhou, Bin, Sun, Jian, Hou, Jinlin
Format: Article
Language:English
Subjects:
Adult
Antigens
Antiretroviral drugs
Antiviral Agents - therapeutic use
Antiviral drugs
Biomarkers
DNA, Viral - blood
Female
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis
Hepatitis B
Hepatitis B Core Antigens - blood
Hepatitis B e antigen
Hepatitis B e Antigens - blood
Hepatitis B surface antigen
Hepatitis B Surface Antigens - blood
Hepatitis B, Chronic - drug therapy
Humans
Interferon
Kaplan-Meier Estimate
Male
Nucleosides - therapeutic use
Patients
Predictive Value of Tests
Proportional Hazards Models
Prospective Studies
Recurrence
Ribonucleic acid
Risk groups
RNA
RNA viruses
Seroconversion
Tenofovir
Tenofovir - therapeutic use
Treatment Outcome
VIRUSES
Withholding Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!